Experimental cancer drug KZR-261 tested in early trial

NCT ID NCT05047536

Terminated Disease control Sponsor: Kezar Life Sciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the data collected helps understand how the drug works in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KZR-261
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This was an early, small Phase 1 trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED / METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma colorectal cancer colorectal neoplasm melanoma mesothelioma metastatic malignant neoplasm neoplasm Neoplasm Metastasis uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED / METASTATIC SOLID TUMOR

Contacts and locations

Locations

Cedars Sinai Medical Center

Los Angeles, California, 90048, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Henry Ford Health System

Detroit, Michigan, 48202, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
START (South Texas Accelerated Research Therapeutics)

San Antonio, Texas, 78229, United States
Sara Cannon Research Institution (SCRI) - Tennessee Oncology Nashville

Nashville, Tennessee, 37203, United States
University Hospitals - Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of California Los Angeles

Los Angeles, California, 90095, United States
Virginia Cancer Specialists (VCS)

Fairfax, Virginia, 22031, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.